Tags

Type your tag names separated by a space and hit enter

Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial.
Int J Cancer. 2014 Dec 01; 135(11):2604-11.IJ

Abstract

Baseline human papillomavirus (HPV) prevalence and type distribution were evaluated in young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials.gov registration NCT00779766). Cervical specimens and blood samples were collected at baseline from women aged 18-25 years (n = 6,051) from four sites across Jiangsu province. Cervical specimens were tested for HPV DNA by SPF10 PCR-DEIA-LiPA25 version 1, and HPV-16/18 type-specific polymerase chain reaction. Anti-HPV-16 and anti-HPV-18 antibody titres were quantified by enzyme-linked immunosorbent assay. At baseline, 15.3% of women were DNA positive for any of 14 HPV high-risk (hr) types (HPV-16/18/31/33/35/39/45/51/52/56/58/59/66/68). The most commonly detected hrHPV types in cervical specimens were HPV-52 (4.0%) and HPV-16 (3.7%). High-risk HPV DNA-positivity increased with severity of cytological abnormalities: 39.3% in atypical squamous cells of undetermined significance, 85.0% in low-grade squamous intraepithelial lesions and 97.8% in high-grade squamous intraepithelial lesions (HSIL). The hrHPV types most frequently detected in HSIL were HPV-16 (63.0%), HPV-18 (17.4%), HPV-52 (17.4%), HPV-58 (15.2%) and HPV-33 (15.2%). The hrHPV types most frequently detected in cervical intraepithelial neoplasia 2+ were HPV-16 (66.1%), HPV-33 (16.1%), HPV-52 (16.1%), HPV-58 (14.5%) and HPV-51 (11.3%). Multiple hrHPV infections were reported for 24.4% of hrHPV DNA positive women. Regardless of baseline HPV DNA status, 30.5% and 16.0% of subjects were initially seropositive for anti-HPV-16 and anti-HPV-18, respectively. In conclusion, the high baseline seropositivity rate and intermediate prevalence of cervical hrHPV types in Chinese women aged 18-25 years underlines the importance of early HPV vaccination in this population.

Authors+Show Affiliations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CICAMS) and Peking Union Medical College, Beijing, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24740547

Citation

Zhao, Fang-Hui, et al. "Baseline Prevalence and Type Distribution of Human Papillomavirus in Healthy Chinese Women Aged 18-25 Years Enrolled in a Clinical Trial." International Journal of Cancer, vol. 135, no. 11, 2014, pp. 2604-11.
Zhao FH, Zhu FC, Chen W, et al. Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. Int J Cancer. 2014;135(11):2604-11.
Zhao, F. H., Zhu, F. C., Chen, W., Li, J., Hu, Y. M., Hong, Y., Zhang, Y. J., Pan, Q. J., Zhu, J. H., Zhang, X., Chen, Y., Tang, H., Zhang, H., Durand, C., Datta, S. K., Struyf, F., & Bi, D. (2014). Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. International Journal of Cancer, 135(11), 2604-11. https://doi.org/10.1002/ijc.28896
Zhao FH, et al. Baseline Prevalence and Type Distribution of Human Papillomavirus in Healthy Chinese Women Aged 18-25 Years Enrolled in a Clinical Trial. Int J Cancer. 2014 Dec 1;135(11):2604-11. PubMed PMID: 24740547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Baseline prevalence and type distribution of human papillomavirus in healthy Chinese women aged 18-25 years enrolled in a clinical trial. AU - Zhao,Fang-Hui, AU - Zhu,Feng-Cai, AU - Chen,Wen, AU - Li,Juan, AU - Hu,Yue-Mei, AU - Hong,Ying, AU - Zhang,Yi-Ju, AU - Pan,Qin-Jing, AU - Zhu,Jia-Hong, AU - Zhang,Xun, AU - Chen,Yong, AU - Tang,Haiwen, AU - Zhang,Helen, AU - Durand,Christelle, AU - Datta,Sanjoy K, AU - Struyf,Frank, AU - Bi,Dan, AU - ,, Y1 - 2014/05/20/ PY - 2013/08/10/received PY - 2014/02/24/revised PY - 2014/02/25/accepted PY - 2014/4/18/entrez PY - 2014/4/18/pubmed PY - 2014/12/15/medline KW - China KW - human papillomavirus KW - prevalence KW - type distribution KW - women SP - 2604 EP - 11 JF - International journal of cancer JO - Int J Cancer VL - 135 IS - 11 N2 - Baseline human papillomavirus (HPV) prevalence and type distribution were evaluated in young Chinese women enrolled in a clinical trial of an HPV vaccine (ClinicalTrials.gov registration NCT00779766). Cervical specimens and blood samples were collected at baseline from women aged 18-25 years (n = 6,051) from four sites across Jiangsu province. Cervical specimens were tested for HPV DNA by SPF10 PCR-DEIA-LiPA25 version 1, and HPV-16/18 type-specific polymerase chain reaction. Anti-HPV-16 and anti-HPV-18 antibody titres were quantified by enzyme-linked immunosorbent assay. At baseline, 15.3% of women were DNA positive for any of 14 HPV high-risk (hr) types (HPV-16/18/31/33/35/39/45/51/52/56/58/59/66/68). The most commonly detected hrHPV types in cervical specimens were HPV-52 (4.0%) and HPV-16 (3.7%). High-risk HPV DNA-positivity increased with severity of cytological abnormalities: 39.3% in atypical squamous cells of undetermined significance, 85.0% in low-grade squamous intraepithelial lesions and 97.8% in high-grade squamous intraepithelial lesions (HSIL). The hrHPV types most frequently detected in HSIL were HPV-16 (63.0%), HPV-18 (17.4%), HPV-52 (17.4%), HPV-58 (15.2%) and HPV-33 (15.2%). The hrHPV types most frequently detected in cervical intraepithelial neoplasia 2+ were HPV-16 (66.1%), HPV-33 (16.1%), HPV-52 (16.1%), HPV-58 (14.5%) and HPV-51 (11.3%). Multiple hrHPV infections were reported for 24.4% of hrHPV DNA positive women. Regardless of baseline HPV DNA status, 30.5% and 16.0% of subjects were initially seropositive for anti-HPV-16 and anti-HPV-18, respectively. In conclusion, the high baseline seropositivity rate and intermediate prevalence of cervical hrHPV types in Chinese women aged 18-25 years underlines the importance of early HPV vaccination in this population. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/24740547/Baseline_prevalence_and_type_distribution_of_human_papillomavirus_in_healthy_Chinese_women_aged_18_25_years_enrolled_in_a_clinical_trial_ L2 - https://doi.org/10.1002/ijc.28896 DB - PRIME DP - Unbound Medicine ER -